返回排名列表

RadNet, Inc. (RDNT)

被高估
HealthcareDiagnostics & ResearchUnited States

基本面

25

价格

$68.94

市值

$5.43B

第一部分 · 这家公司值多少

概览

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States and internationally. The company operates in two segments, Imaging Centers and Digital Health. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretations of breast, lung, and prostate images, as well as solutions for prostate cancer screening. In addition, it develops and delivers AI-powered health informatics solutions to drive quality, efficiency, and outcomes in imaging and radiology; informatics designed for outpatient radiology; and DeepHealth OS, a cloud-native operating system that helps in the operations of the radiology service. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

资产负债表与流动性

营收

$2.27B

最近12个月(截至2026/6/30)

净利润

$-21M

最近12个月(截至2026/6/30)

自由现金流

-

股东权益合计

$1.09B

负债合计

$2.40B

流动比率

1.48

利息覆盖率

0.99

债务/EBITDA

10.20

每股收益

营收与净利润

自由现金流

收入构成

历史财务表

利润率变化

债务变化

债务负担有多重

增长一览表

增长 — 营业收入

公允价值估算

一般情形被高估

公允价值

$53.26

当前价格

$68.94

安全边际

-29.4%

公允价值区间

$34.62 - $71.90

所用估值方法之间的离散区间,并非经过统计校准的置信区间。

估算方法

分析师目标价:$94.63
现金流折现法(DCF):$14.05
市盈率法(P/E):数据不足,无法计算
格雷厄姆成长公式:数据不足,无法计算
盈利能力价值(EPV):$5.42
合理市净率(P/B):数据不足,无法计算
股息折现模型(戈登模型):数据不足,无法计算
P/FFO(运营资金):$27.14
周期中段收益:$30.81
市销率法(P/S):$113.54
分析师共识:强力买入 (13B / 1H / 0S)
最近财报超预期:+40.16%

估值指标

市盈率(P/E)

-

ROE

-1.7%

市净率(P/B)

4.95

P/FCF

-

毛利率

-

ROIC

1.6%

盈利能力雷达图

价值创造(经济护城河)

ROIC

1.6%

WACC

9.6%

ROIC − WACC

-8.1 pp

ROIC 低于资本成本:公司每投入一美元都在毁灭价值。

基本面分析标准

通过(6)

  • Price CAGR 27.50%
  • Debt/Equity ratio
  • Current Ratio
  • Revenue Growth 5Y 13.7%
  • Analyst Consensus 93% Buy
  • Earnings Surprise avg 3.7%

未通过(13)

  • EPS shows upward trend
  • ROIC 1.6%
  • P/B Ratio 4.95
  • Operating Margin 3.1%
  • Interest Coverage
  • Debt/EBITDA
  • Return on Tangible Assets
  • Low reliance on intangibles
  • DCF valuation (Overvalued)
  • ROE -1.9%
  • Share Dilution 6.8%
  • Net Margin Trend -0.9% vs -0.8%
  • Piotroski F-Score 3/9

不可用(8)

  • Gross Margin NaN%
  • P/FCF NaN
  • Dividend Payout NaN%
  • Positive Free Cash Flow
  • CapEx intensity
  • Price below Graham Number
  • PEG Ratio (need PE > 0 and growth > 0)
  • Earnings Quality (OCF/Net Income)

Piotroski F-评分

3/9

存在严重财务隐患

score
criteria

盈利质量

-

低质量:需深入审查会计处理

股权稀释

6.8%

正在发行新股,稀释所有权

机构持股

公司治理

管理团队

姓名职位年龄
Dr. Howard G. Berger M.D.Chairman, President & CEO79
Mr. Mark D. StolperExecutive VP & CFO54
Mr. Mital PatelExecutive VP & COO39
Mr. Norman R. HamesPresident & CEO of Western Operations69
Mr. Stephen M. ForthuberPresident & CEO of Eastern Operations64
Dr. Alma Gregory Sorensen M.D.Executive VP, Chief Strategy Officer & Director63
Ms. Susan HollabaughChief Information Officer-
Mr. David Jeffrey Katz Esq.Executive VP, Chief Legal Officer & Corporate Secretary61
Mr. David ManheimSenior VP & Chief Compliance Officer-
Mr. Michael M. MurdockExecutive Vice President of Mergers & Acquisitions70

审计风险

8

董事会风险

8

薪酬风险

7

股东权利风险

2

第二部分 · 价格与买入时机

这一部分不判断公司是否值得拥有:它帮助你在基本面说服你之后,选择何时买入。包含:技术分析、潜力、历史回撤、Gamma 敞口。

文件

  • 年度报告(10-K)

    对公司业务、财务业绩和风险的年度概述。

    提交日期:2026-03-02

    查看文件
  • 季度报告(10-Q)

    最近三个月财务表现的最新情况。

    提交日期:2026-08-10

    查看文件
  • 临时报告(8-K)

    关于重大事件(如管理层变动或重要公告)的通知。

    提交日期:2026-08-14

    查看文件

via SEC EDGAR

损益历史

via SEC EDGAR

Latest News

Recent headlines for RDNT, sourced from Markets Gazette.

  • 3/2/2026NEUTRAL
    RadNet (RDNT) Q4 2025 Earnings Call Transcript

    The transcript for RadNet Inc.'s (RDNT) Q4 2025 earnings call is now available to investors. While access to such documents is crucial for understanding the company's financial performance and future outlook, the current lack of specific content details prevents an immediate assessment of market impact. Analysts and investors are awaiting a review of key data, management statements, and projections to evaluate RadNet's operational and strategic health. Earnings calls are pivotal moments for grasping growth trends, profit margins, and any potential challenges the company might face in the diagnostic imaging services sector. Without the content, the signal remains neutral, pending further insights.

  • 3/2/2026NEUTRAL
    RadNet Earnings Review: Q4 Summary

    Markets Gazette notes the announcement of RadNet's Q4 earnings review. While the title suggests an upcoming analysis of the company's financial performance, the provided article lacks specific details regarding the results, such as revenue figures, earnings per share, or future projections. This absence of concrete data prevents investors from assessing RadNet's current financial health or anticipating potential market movements. Traders are eagerly awaiting further information to formulate informed investment strategies.

via Markets Gazette